Physician profile
Nathan Stephens
NPI 1154826683
$1,192.79
in general payments reported to CMS, 2019-2025
16 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $140 · 2023: $437 · 2024: $413 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $270.07 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $141.71 | 2023-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $126.24 | 2023-2025 | |
| Exact Sciences Corporation | $107.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $99.28 | 2022-2024 | |
| Abbott Laboratories | $89.62 | 2023-2025 | Freestyle Libre 3 |
| Abbvie INC. | $67.23 | 2023-2025 | Vraylar |
| Axsome Therapeutics, INC. | $52.15 | 2024-2025 | Auvelity |
| Dexcom, INC. | $46.25 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company Ltd. | $41.89 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $35.97 | 2023-2024 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $34.70 | 2024-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $24.02 | 2022 | |
| Merck Sharp & Dohme LLC | $22.05 | 2023 | Verquvo, Belsomra, Steglatro |
| Mycovia Pharmaceuticals, INC. | $19.99 | 2023 | Vivjoa |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $13.77 | 2023 | Aptima, Thinprep 2000 Processor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.